Skip to main content
Ami B. Patel
( out of 47 reviews )

Ami B. Patel, MD

Languages spoken: English
  • .

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    5.0 /5
    ( out of 47 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    July 25, 2023
    HUNTSMAN CANCER CENTER

    Dr. Patel was familiar with my case and listened to my concerns. She was interested in exploring some other ideas and messaged my with additional information concerning lab results. I found her to be caring, knowledgeable, and concerned about my health. Wonderful provider!

    May 31, 2023
    HUNTSMAN CANCER CENTER

    Very detail oriented, caring, friendly and well prepare for every single visit

    May 07, 2023
    HUNTSMAN CANCER CENTER

    She was very kind, explained things clearly,

    April 09, 2023
    HUNTSMAN CANCER CENTER

    She diligently explained my condition and we made a plan for future events. I love her attitude, she made me feel so comfortable and hopeful.

    March 11, 2023
    HUNTSMAN CANCER CENTER

    Excellent doctor. Skilled and knowledgeable

    March 05, 2023
    HUNTSMAN CANCER CENTER

    Is is clear that Dr. Patel is extremely knowledgeable. She was very kind, compassionate, and thorough during our appointment. I feel beyond lucky to be under her care.

    February 18, 2023
    HUNTSMAN CANCER CENTER

    Doctor Patel is an excellent doctor.

    February 09, 2023
    HUNTSMAN CANCER CENTER

    Dr. Patel is a first class physician. She makes me feel like I matter and I have a great deal of confidence in her care.

    January 28, 2023
    HUNTSMAN CANCER CENTER

    She listens intently and responds thoughtfully. She always seems upbeat and encouraging.

  • .

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Hematology/Oncology Research - University of Utah Advanced Fellow
    Hematology/Oncology Fellowship Program - University of Utah School of Medicine Chief Fellow
    Fellowship Hematology/Oncology - University of Utah School of Medicine Fellow
    Internal Medicine - McGaw Medical Center of Northwestern University Resident
    Internship Internal Medicine - McGaw Medical Center of Northwestern University Intern
    Medicine - Northwestern University Feinberg School of Medicine M.D.
    Undergraduate Biology - Northwestern University B.S.

    Selected Publications

    Journal Article

    1. Patel AB, Deininger MW (2020). Genetic complexity of chronic myelomonocytic leukemia. Leuk Lymphoma, 62(5), 1031-1045. (Read full article)
    2. Yan D, Franzini A, Pomicter AD, Halverson BJ, Antelope O, Mason CC, Ahmann JM, Senina AV, Vellore NA, Jones CL, Zabriskie MS, Than H, Xiao MJ, van Scoyk A, Patel AB, Clair PM, Heaton WL, Owen SC, Andersen JL, Egbert CM, Reisz JA, DAlessandro A, Cox JE, Gantz KC, Redwine HM, Iyer SM, Khorashad JS, Rajabi N, Olsen CA, OHare T, Deininger MW (2019). SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIA. Blood Cancer Discov, 2(3), 266-287. (Read full article)
    3. Patel AB, Pomicter AD, Yan D, Eiring AM, Antelope O, Schumacher JA, Kelley TW, Tantravahi SK, Kovacsovics TJ, Shami PJ, OHare T, Deininger MW (2020). Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. Leukemia, 34(11), 2981-2991. (Read full article)
    4. Patel AB, Franzini A, Leroy E, Kim SJ, Pomicter AD, Genet L, Xiao M, Yan D, Ahmann JM, Agarwal AM, Clair P, Addada J, Lambert J, Salmon M, Gleich GJ, Cross NCP, Constantinescu SN, OHare T, Prchal JT, Deininger MW (2019). JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Blood, 134(26), 2388-2398. (Read full article)
    5. Antelope O, Vellore NA, Pomicter AD, Patel AB, Van Scoyk A, Clair PM, Deininger MW, OHare T (2019). BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia. Exp Hematol, 77, 36-40.e2. (Read full article)
    6. Patel AB, Miles RR, Deininger MW (2019). Lysozyme nephropathy in chronic myelomonocytic leukemia. Clin Case Rep, 7(6), 1263-1264. (Read full article)
    7. Patel AB, Pettijohn EM, Abedin SM, Raps E, Deininger MW (2019). Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations. Blood Adv, 3(7), 952-955. (Read full article)
    8. Patel AB, Chen YH, Zhang Y, Frankfurt O, Winter JN (2014). Achievement of morphologic and cytogenetic remission with single-agent hydroxyurea in a patient with acute myeloid leukemia with inv(16). Leuk Lymphoma, 56(3), 817-9. (Read full article)